Phase 1b Dose Escalation followed by Phase 2 treatment. Participants will be evaluable for inclusion in the Phase 1b and Phase 2 portions of the study if they receive at least one dose of protocol therapy.
What is the purpose of this trial?
The main purpose of this study is to determine the safe and recommended dose of APR-246 in combination with azacitidine as well as to see if this combination of therapy improves overall survival.
- Trial withAprea Therapeutics AB
- Start Date06/19/2019
- End Date05/30/2020
- Last Updated08/07/2019
- Study HIC#2000024507